Cytek Biosciences - CTKB Enterprise Value-to-Revenue Multiple

Public company logo of cytekbio.com (CTKB)

Proprietary spectral cytometry creates robust barriers for competitors, while large-scale investments in laser software ensure the technological priority of Cytek Biosciences (CTKB). Analyzing the firm's EV/Sales multiple valuation on GURU.Markets, we find that the 2905.23 mark serves as a relevant indicator. The integration of instruments with software has formed a unique cell analysis ecosystem, which has become a fundamental tool for modern biologists.

CTKB Cytek Corp Company Value to Revenue (11/23/2025 - 11/20/2026)

Cytek Corp - analytical breakdowns and key metrics (CTKB)

- stock price and consensus target price:
Initial company analysis:CTKB, cytekbio.com
Flagship merchandise of Cytek Bio

This indicator compares the total enterprise value, including debt, with the volume of generated sales. It allows for the exclusion of the impact of debt load on market valuation, separating fundamental value from price volatility. By analyzing the enterprise value-to-revenue multiple, an investor determines the degree of overpayment for the asset. For Cytek Biosciences, Inc. (CTKB), a high valuation is justified by the monopoly status of the Aurora software. This creates switching barriers for customers, ensuring a stable cash flow.

Competitor analysis

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|Company Value to Revenue EXAS|Revvity, Inc. (RVTY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple BIO|NNNN (Anbio Biotechnology) - Business Value to Revenue|EV/Sales Multiple SHC (Sotera Health)|Quidel Corporation (QDEL) - Enterprise Value-to-Revenue Multiple|OPK - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio CareDx Corp CDNA|Maravai LifeSciences (MRVI) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Sales Ratio Fulgent Genetics, Inc. FLGT|LAB (Standard BioTools Inc) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple OraSure OSUR|Company Value to Revenue XGN (Exagen Diagnostics)|Total Company Value-to-Revenue Ratio MDxHealth Inc.|Enterprise Value-to-Revenue Ratio Lucid Diagnostics, Inc. LUCD|Prenetics Global Ltd (PRE) - Enterprise Value-to-Revenue Multiple|Insight Molecular Diagnostics Inc - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple trinitybiotech.com|PRPH (ProPhase) - Company Value to Revenue|Company Value to Revenue Ratio AIMD|Company Value to Revenue CODX|Enterprise Value-to-Revenue Multiple heartsciences.com HSCS|Enterprise Value-to-Revenue Ratio Biomerica Inc. (BMRA)|Total Company Value-to-Revenue Ratio Cardio Diagnostics Holdings|EV/Sales Multiple ONCO (Onconetix Corporation)|Virax Biolabs Group (VRAX) - Enterprise Value-to-Revenue Multiple|bluejaydx.com - EV/Sales Multiple|Aspira Women's Health - Enterprise Value-to-Revenue Coefficient|AXDX (Accelerate Diagnostics) - Company Value to Revenue|Company Value to Revenue CENTOGENE, N.V.|Enterprise Value-to-Revenue Ratio enzo.com|EV/Sales Multiple Fresh2 Group Limited|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue